Moderna's Ups and Downs: Here's What You Need to Know Before Investing.
2026-02-25 08:35:00 ET
Moderna (NASDAQ: MRNA) soared into the spotlight during the pandemic thanks to its mRNA technology and its rapid development of a coronavirus vaccine. But it's those two elements that have weighed on the stock in more recent times: The U.S. last year ended about $500 million in funding for mRNA vaccine development. And the coronavirus vaccine, facing lower demand, is no longer delivering the same levels of revenue that it did at its peak.
The company has had its ups -- the approval of its respiratory syncytial virus (RSV) vaccine back in 2024 -- and its downs -- the failure of its cytomegalovirus (CMV) vaccine candidate in a phase 3 trial a few months ago.
If you're thinking about buying Moderna stock, here's what you need to know first.
NASDAQ: MRNA
MRNA Trading
1.4% G/L:
$54.50 Last:
3,621,646 Volume:
$55.0309 Open:
